



SEP 26 2001
UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

Laura A. Coruzzi
Pennie & Edmunds LLP
1155 Avenue of the Americas
New York, NY 10036-2711

In re Application of: :
Wrigley et al. :
Application No.: 09/284806 : DECISION ON
PCT No.: PCT/GB97/02907 :
Int. Filing Date: 21 October 1997 : PETITION UNDER
Priority Date: 21 October 1996 :
Attorney's Docket No.: 117-284 : 37 CFR 1.137(b)
For: Cytokine Production Inhibitors :

This is in response to the petition filed on 07 June 2001, which requests reconsideration under 37 CFR 1.137(b).

DISCUSSION

A grantable petition to revive an abandoned application under 37 CFR 1.137(b) must be accompanied by (1) the required reply, unless previously filed; (2) the petition fee as set forth in § 1.17(m); (3) a statement that the entire delay in filing the required reply from the due date for the reply until the filing of a grantable petition pursuant to this paragraph was unintentional. The Commissioner may require additional information where there is a question whether the delay was unintentional; and (4) any terminal disclaimer (and fee as set forth in § 1.20 (d)) required pursuant to paragraph (c) of this section.


Regarding requirement (1), the renewed petition is accompanied by the required reply in the form of a satisfactory declaration of the inventors. Accordingly, all of the requirements of 37 CFR 1.137(b) have now been satisfied.

DECISION

For the reasons explained above, the petition is **GRANTED**.

This application is being returned to the United States Designated/Elected Office (DO/EO/US) for further processing. The date of this application under 35 U.S.C. 371 is **7 June 2001**.


Richard Cote
PCT Legal Examiner
PCT Legal Office


George M. Dombroske
PCT Legal Examiner
PCT Legal Office
Tel: (703) 308-6721
Fax: (703) 308-6459